<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02233101</url>
  </required_header>
  <id_info>
    <org_study_id>RUSH2233</org_study_id>
    <nct_id>NCT02233101</nct_id>
  </id_info>
  <brief_title>Oral vs. Intravenous TXA Study Proposal: TJA</brief_title>
  <official_title>Oral vs. Intravenous TXA Study Proposal: TJA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: Examine oral and intravenous Tranexamic Acid (TXA) to determine whether or not the&#xD;
      different routes of drug administration are equivalent in terms of post-operative reduction&#xD;
      in hemoglobin, number of transfusions, and post-operative blood loss following TJA surgery.&#xD;
&#xD;
      Hypothesis: Oral and intravenous TXA are equivalent routes of drug administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: Examine oral and intravenous Tranexamic Acid (TXA) to determine whether or not the&#xD;
      different routes of drug administration are equivalent in terms of post-operative reduction&#xD;
      in hemoglobin, number of transfusions, and post-operative blood loss following TJA surgery.&#xD;
&#xD;
      Hypothesis: Oral and intravenous TXA are equivalent routes of drug administration.&#xD;
&#xD;
      Background/Scientific review:&#xD;
&#xD;
      Total hip or knee arthroplasty is associated with the risk of moderate to significant blood&#xD;
      loss. Techniques such as the use of antifibrinolytics or desmopressin, or normovolaemic&#xD;
      haemodilution have been used to reduce the need for allogeneic blood transfusion. Tranexamic&#xD;
      acid (TXA) has been used to reduce blood loss and transfusion requirement for total hip and&#xD;
      knee arthroplasty, with good results. Approximately one-third of patients undergoing total&#xD;
      joint replacement surgery require one to three units of blood postoperatively. Tranexamic&#xD;
      acid is a synthetic antifibrinolytic agent that has been successfully used intravenously to&#xD;
      control bleeding after total joint replacement. The use of TXA has been shown to&#xD;
      significantly reduce the need for blood products during total joint replacement1-4.&#xD;
&#xD;
      There are only a few studies directly comparing outcomes following the use of intravenous&#xD;
      tranexamic acid (IVTA) and oral tranexamic acid (OTA) in arthroplasty surgery. In the&#xD;
      randomized study by Zohar et al5. OTA (n = 20) was associated with significant allogeneic&#xD;
      blood sparing com- pared with controls (n = 20), but not when compared with short- and&#xD;
      long-term IVTA regimens. A recent randomized trial comparing OTA (n = 26) with placebo (n =&#xD;
      20) reported significant reductions in blood drained at 24 hours, and in the fall of both Hb&#xD;
      and Hct in the OTA group, without any significant difference in the requirement of&#xD;
      transfusion6.&#xD;
&#xD;
      Study Design: Prospective, randomized, single-blinded study&#xD;
&#xD;
      Treatment Groups:&#xD;
&#xD;
        1. Intravenous TXA Group - 1 gram IV bolus 10 minutes prior to incision&#xD;
&#xD;
        2. Oral TXA Group - 3 tablets (1950 mg) oral 2 hours prior to incision&#xD;
&#xD;
      Demographics/Patient Specifics: Age, Sex, ASA score, Weight, Height, Estimated&#xD;
      intra-operative blood loss, Intra-operative fluids (crystalloid, colloid), Operative time,&#xD;
      Hospitalization days, BMI, Pre-operative PT/INR, Pre-operative PTT, Pre-operative platelet&#xD;
      count&#xD;
&#xD;
      Outcome Measurements:&#xD;
&#xD;
        1. Post-operative reduction in Hgb - Measure pre-operative Hgb levels and post-operative&#xD;
           days 0, 1, 2, and 3 Hgb levels. Among the studies presented, they used different time&#xD;
           points to determine the reduction in Hgb. They either used the post-operative 12-hour&#xD;
           Hgb, post-operative day 4 Hgb, or the lowest Hgb during the hospitalization. Because we&#xD;
           rarely have patients stay until post-operative day 4, we will have to make our measure&#xD;
           off a different time period. We have patients get discharged as early as post-operative&#xD;
           day 1, so we'll probably have to use the post-operative day 1 Hgb level. We feel a Hgb&#xD;
           level difference of &gt;1 g/dL is clinically significant.&#xD;
&#xD;
        2. Post-operative reduction in Hematocrit - Measure pre-operative and post-operative days&#xD;
           0, 1, 2, and 3 Hematocrit levels&#xD;
&#xD;
        3. Number of units transfused&#xD;
&#xD;
        4. Number of patients transfused&#xD;
&#xD;
        5. Cost comparison - Cost differences resulted from differences in the blood transfusion&#xD;
           rate, length of hospital stay, and management of complications as well as from the cost&#xD;
           of the TXA itself&#xD;
&#xD;
        6. Complications&#xD;
&#xD;
             1. DVT or PE&#xD;
&#xD;
             2. Return to the OR within 30 days&#xD;
&#xD;
             3. Re-admission within 30 days&#xD;
&#xD;
             4. Superficial infection&#xD;
&#xD;
             5. Deep infection&#xD;
&#xD;
             6. Periprosthetic fracture&#xD;
&#xD;
             7. Cerebrovascular accident or Transient ischemic attack&#xD;
&#xD;
             8. Dislocation&#xD;
&#xD;
      Risks/Benefits&#xD;
&#xD;
      The use of Tranexamic Acid is a standard of care used everyday in both primary and revision&#xD;
      surgeries, this includes both oral and intravenous forms of Tranexamic Acid. TXA side effects&#xD;
      include of nausea, vomiting and/or diarrhea. Gastrointestinal upset could occur with Oral&#xD;
      tranexamic acid.&#xD;
&#xD;
      The only risk involved is the potential for breach of confidentiality and/or privacy. Below&#xD;
      is a description of the procedure for maintaining confidentiality. There is no direct benefit&#xD;
      to the participants in this study.&#xD;
&#xD;
      Procedures for Maintaining Confidentiality&#xD;
&#xD;
      A breach of confidentiality and/or privacy is a risk of this study. To prevent this, all&#xD;
      collected data will be stored electronically in password-protected files to protect patient&#xD;
      identity and information. All information will be collected and reviewed by the research team&#xD;
      only. Data will be maintained on a password-protected computer that will be accessible only&#xD;
      to the study team. No patient identifiers will be maintained in the database.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Required Blood Transfusion</measure>
    <time_frame>during or within 24 hours after surgery</time_frame>
    <description>Patient hemoglobin will be measured during and after surgery for the first 24 hours to determine if a blood transfusion is indicated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other Complications</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of no more than 30 days</time_frame>
    <description>Any other complications listed below:&#xD;
DVT or PE&#xD;
Return to the OR within 30 days&#xD;
Re-admission within 30 days&#xD;
Superficial infection&#xD;
Deep infection&#xD;
Periprosthetic fracture&#xD;
Cerebrovascular accident or Transient ischemic attack&#xD;
Dislocation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">167</enrollment>
  <condition>Blood Loss After Primary Total Joint Arthroplasty</condition>
  <condition>Need for Blood Transfusion After Total Joint Arthroplasty</condition>
  <arm_group>
    <arm_group_label>Oral Tranexamic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive either oral or intravenous Tranexamic Acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous Tranexamic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive either oral or intravenous Tranexamic Acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Tranexamic Acid</intervention_name>
    <description>patients will receive 1950mg of oral prior to surgery to help reduce blood loss during total joint replacement</description>
    <arm_group_label>Oral Tranexamic Acid</arm_group_label>
    <other_name>TXA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Tranexamic Acid</intervention_name>
    <description>Patients will receive 1950mg of intravenous Tranexamic Acid prior to total joint arthroplasty and blood loss or need for transfusion within 24 hours post operative</description>
    <arm_group_label>Intravenous Tranexamic Acid</arm_group_label>
    <other_name>TXA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any patient scheduled for a primary TKA or cementless THA with epidural/spinal&#xD;
             anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to TXA, acquired disturbances of color vision, refusal of blood products,&#xD;
             pre-op use of anticoagulant therapy within five days before surgery, a history of&#xD;
             arterial or venous thromboembolic disease (such as DVT, PE, CVA, TIA), pregnancy,&#xD;
             breastfeeding, major comorbidities (such as severe ischemic heart disease [New York&#xD;
             Heart Association Class III or IV], previous myocardial infarction, severe pulmonary&#xD;
             disease, renal impairment, or hepatic failure), patients who decline to participate,&#xD;
             any patient undergoing a revision TKA, THA or BHR&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig J Della Valle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>June 26, 2014</study_first_submitted>
  <study_first_submitted_qc>September 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2014</study_first_posted>
  <results_first_submitted>March 20, 2017</results_first_submitted>
  <results_first_submitted_qc>March 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 28, 2017</results_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oral Tranexamic Acid</title>
          <description>Patients will receive either oral or intravenous Tranexamic Acid&#xD;
Oral Tranexamic Acid: patients will receive 1950mg of oral prior to surgery to help reduce blood loss during total joint replacement</description>
        </group>
        <group group_id="P2">
          <title>Intravenous Tranexamic Acid</title>
          <description>Patients will receive either oral or intravenous Tranexamic Acid&#xD;
Intravenous Tranexamic Acid: Patients will receive 1950mg of intravenous Tranexamic Acid prior to total joint arthroplasty and blood loss or need for transfusion within 24 hours post operative</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Tranexamic Acid</title>
          <description>Patients will receive either oral or intravenous Tranexamic Acid&#xD;
Oral Tranexamic Acid: patients will receive 1950mg of oral prior to surgery to help reduce blood loss during total joint replacement</description>
        </group>
        <group group_id="B2">
          <title>Intravenous Tranexamic Acid</title>
          <description>Patients will receive either oral or intravenous Tranexamic Acid&#xD;
Intravenous Tranexamic Acid: Patients will receive 1950mg of intravenous Tranexamic Acid prior to total joint arthroplasty and blood loss or need for transfusion within 24 hours post operative</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="86"/>
            <count group_id="B2" value="81"/>
            <count group_id="B3" value="167"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="37" upper_limit="87"/>
                    <measurement group_id="B2" value="58" lower_limit="30" upper_limit="85"/>
                    <measurement group_id="B3" value="60" lower_limit="30" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Required Blood Transfusion</title>
        <description>Patient hemoglobin will be measured during and after surgery for the first 24 hours to determine if a blood transfusion is indicated.</description>
        <time_frame>during or within 24 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Tranexamic Acid</title>
            <description>Patients will receive either oral or intravenous Tranexamic Acid&#xD;
Oral Tranexamic Acid: patients will receive 1950mg of oral prior to surgery to help reduce blood loss during total joint replacement</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Tranexamic Acid</title>
            <description>Patients will receive either oral or intravenous Tranexamic Acid&#xD;
Intravenous Tranexamic Acid: Patients will receive 1950mg of intravenous Tranexamic Acid prior to total joint arthroplasty and blood loss or need for transfusion within 24 hours post operative</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Required Blood Transfusion</title>
          <description>Patient hemoglobin will be measured during and after surgery for the first 24 hours to determine if a blood transfusion is indicated.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other Complications</title>
        <description>Any other complications listed below:&#xD;
DVT or PE&#xD;
Return to the OR within 30 days&#xD;
Re-admission within 30 days&#xD;
Superficial infection&#xD;
Deep infection&#xD;
Periprosthetic fracture&#xD;
Cerebrovascular accident or Transient ischemic attack&#xD;
Dislocation</description>
        <time_frame>participants will be followed for the duration of hospital stay, an expected average of no more than 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Tranexamic Acid</title>
            <description>Patients will receive either oral or intravenous Tranexamic Acid&#xD;
Oral Tranexamic Acid: patients will receive 1950mg of oral prior to surgery to help reduce blood loss during total joint replacement</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Tranexamic Acid</title>
            <description>Patients will receive either oral or intravenous Tranexamic Acid&#xD;
Intravenous Tranexamic Acid: Patients will receive 1950mg of intravenous Tranexamic Acid prior to total joint arthroplasty and blood loss or need for transfusion within 24 hours post operative</description>
          </group>
        </group_list>
        <measure>
          <title>Other Complications</title>
          <description>Any other complications listed below:&#xD;
DVT or PE&#xD;
Return to the OR within 30 days&#xD;
Re-admission within 30 days&#xD;
Superficial infection&#xD;
Deep infection&#xD;
Periprosthetic fracture&#xD;
Cerebrovascular accident or Transient ischemic attack&#xD;
Dislocation</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Oral Tranexamic Acid</title>
          <description>Patients will receive either oral or intravenous Tranexamic Acid&#xD;
Oral Tranexamic Acid: patients will receive 1950mg of oral prior to surgery to help reduce blood loss during total joint replacement</description>
        </group>
        <group group_id="E2">
          <title>Intravenous Tranexamic Acid</title>
          <description>Patients will receive either oral or intravenous Tranexamic Acid&#xD;
Intravenous Tranexamic Acid: Patients will receive 1950mg of intravenous Tranexamic Acid prior to total joint arthroplasty and blood loss or need for transfusion within 24 hours post operative</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Craig J. Della Valle, MD</name_or_title>
      <organization>Rush University Medical Center</organization>
      <phone>312-432-2350</phone>
      <email>craigdellavalle@rushortho.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

